22.89 +0.36 (1.60%)
MYL
| Trade MYL now with |
|
Stock Details
Last Trade:22.89 Change:+0.36 (1.60%) Prev Close:22.53 Open: 22.53 Days Range:22.44 – 22.91 52 Week Range: 15.49 - 25.46 Volume:4689547 P/E: 25.72EPS:0.89
View AllRecent Alerts 02/09/12
Recent Alert on 02/06/12 at 9:29am
Canaccord Genuity on Life Sciences/Specialty Pharmaceuticals: Q4/11 Preview: Post-2012 Message a Growing Focus: WPI and IPXL Top Ideas
Canaccord Genuity on Life Sciences/Specialty Pharmaceuticals: Q4/11 Preview: Post-2012 Message a Growing Focus: WPI and IPXL Top Ideas
Canaccord Genuity on Life Sciences/Specialty Pharmaceuticals: Q4/11 preview: post-2012 message a growing focus; WPI and IPXL top ideas Analyst, Randall Stanicky, said, "Calendar Q4 earnings will be a non-event for most – but other catalysts... Read More
Recent Alert on 02/06/12 at 8:22am
Needham & Company Maintains a 'Strong Buy' on Mylan (MYL)l Mid-May Is D-Day for Generic Lidoderm, Not July
Needham & Company Maintains a 'Strong Buy' on Mylan (MYL)l Mid-May Is D-Day for Generic Lidoderm, Not July
Recent Alert on 02/02/12 at 7:32am
Mylan (MYL) Unit Gets Tentative FDA Approval for Generic Lipitor Tabs (PFE)
Mylan (MYL) Unit Gets Tentative FDA Approval for Generic Lipitor Tabs (PFE)
Recent Alert on 02/02/12 at 7:32am
Mylan (MYL) Unit Gets Tentative FDA Approval for Generic Lipitor Tabs (PFE)
Mylan (MYL) Unit Gets Tentative FDA Approval for Generic Lipitor Tabs (PFE)
Recent Alert on 01/12/12 at 1:55pm
UBS on U.S. Pharma – Large Cap and Specialty: 4Q11 Preview: Things Still Look Interesting
UBS on U.S. Pharma – Large Cap and Specialty: 4Q11 Preview: Things Still Look Interesting
View AllRecent Press Releases
Press Release on 02/06/12 at 8:00am
Mylan Completes Acquisition of Two Limited-Competition Dermatological Products from Valeant
Mylan Completes Acquisition of Two Limited-Competition Dermatological Products from Valeant
Press Release on 02/06/12 at 8:00am
Valeant Pharmaceuticals Completes Divestiture of Generic Dermatology Products to Mylan
Valeant Pharmaceuticals Completes Divestiture of Generic Dermatology Products to Mylan